医药企业大考临近

The challenge to pharmaceutical enterprises is approaching

以取消政府定价为要义的新一轮药价改革,将使一大批医药企业面临更多挑战。究竟有怎样的后续配套改革机制？这一点不仅牵动着药企乃至整个医疗行业的神经,也正在检验政府权责的边界以及政府与市场的关系这项新政在医疗市场引发的反应,明显没有人们此前想象的那么剧烈。

The aim of the new round of drug price reform is to cancel government control price policy,there are more pharmaceutical enterprises facing more challenge.What kind of follow-up reforms will be published? It not only touches the most sensitive nerve of pharmaceutical enterprise and the medicinal industry,but also testing official accountability limits and the relationship between the government and market.